Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor
Open Access
- 1 March 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (3), 289-292
- https://doi.org/10.1093/jac/dkh558
Abstract
BMS-433771 is an orally bioavailable respiratory syncytial virus (RSV) inhibitor, functioning through inhibition of viral F protein-induced membrane fusion. The compound is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 is also efficacious against RSV infection in two rodent models when dosed orally prior to infection. The compound possesses good pharmacokinetic properties, while maintaining a favourable toxicity profile. Consequently, BMS-433771 is well suited for further clinical evaluation in humans. Direct affinity labelling studies indicate that the compound binds in a hydrophobic cavity within the trimeric N-terminal heptad repeat. During the fusion process, this heptad repeat associates with a C-terminal heptad repeat to form a six helical coiled-coil bundle (or trimer-of-hairpins), and BMS-433771 presumably interferes with the functional association of these heptad repeats. The fusion protein of many other class 1 fusion viruses, such as HIV and influenza, form similar hairpin structures as a prelude to membrane fusion. The identification of BMS-433771 provides a proof of concept for small molecule inhibitors that target the formation of the six helical coiled-coil structure, which could be a prototype for the development of similar antivirals against other class 1 fusion viruses.Keywords
This publication has 16 references indexed in Scilit:
- Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusionProceedings of the National Academy of Sciences of the United States of America, 2004
- Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivativesBioorganic & Medicinal Chemistry Letters, 2004
- Orally Active Fusion Inhibitor of Respiratory Syncytial VirusAntimicrobial Agents and Chemotherapy, 2004
- Development of a photoaffinity label for respiratory syncytial virus inhibitorsJournal of Labelled Compounds and Radiopharmaceuticals, 2003
- Fundamental structure–Activity relationships associated with a new structural class of respiratory syncytial virus inhibitorBioorganic & Medicinal Chemistry Letters, 2003
- Importance of Respiratory Viruses in Acute Otitis MediaClinical Microbiology Reviews, 2003
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2003
- Structural characterization of the human respiratory syncytial virus fusion protein coreProceedings of the National Academy of Sciences of the United States of America, 2000
- Respiratory Syncytial Virus Infection in AdultsClinical Microbiology Reviews, 2000
- Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.Proceedings of the National Academy of Sciences of the United States of America, 1996